ArticleNeuro-oncology advances
A phase 1 trial of iron metabolism-targeting oral gallium maltolate in recurrent and refractory glioblastoma.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gallium maltolate is an oral compound that disrupts iron-dependent glioblastoma (GBM) growth and prolongs survival in animal models. This Phase 1 trial of oral gallium maltolate in patients with recurrent GBM was conducted to assess toxicity, determine a recommended Phase 2 dose (RP2D), and seek signals of tumor response. Methods: Using a 3 + 3 dose-escalation design with 5 drug dose levels of oral gallium maltolate (500-2,500 mg daily), 24 patients received a minimum of one 4-week cycle to assess toxicity, and 22 of these patients received a minimum of 2 cycles to assess tumor response. Patients with stable disease on MRI at 8 weeks continued treatment until progression. Results: Grade 1 or 2 adverse effects of diarrhea, anorexia, nausea, and fatigue occurred in 24 patients. The RP2D was determined by considering diarrhea requiring treatment and serum gallium levels that plateaued at doses of 2,000-2,500 mg/day. ALT elevation occurred in 1 patient each on 1,000 and 2,000 mg/day. RBC MCV decreased below normal during treatment in 9 patients. Nephrotoxicity was not seen. GBM progressed in 11 of 22 evaluable patients after 2 cycles and in 6 following 3-6 cycles. Three patients progressed after 8, 10, and 26 cycles. One patient with a stable partial response remains on treatment after 33 cycles. The median overall survival was 16 months. Conclusions: Oral gallium maltolate is safe and well-tolerated with an RP2D of 2,000 mg/day. Further investigation to assess the clinical efficacy of gallium maltolate in GBM is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.